Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update

Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update

Lung cancer (LC) is the leading cause of cancer-related deaths, responsible for approximately 18.4% of all cancer mortalities in both sexes combined. The use of systemic therapeutics remains one of the primary treatments for LC. However, the therapeutic efficacy of these agents is limited due to the...

Full description

Bibliographic Details
Main Authors: Ibrahim M. Abdulbaqi, Reem Abou Assi, Anan Yaghmur, Yusrida Darwis, Noratiqah Mohtar, Thaigarajan Parumasivam, Fadi G. Saqallah, Habibah A. Wahab
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Pharmaceuticals
Subjects:
lung cancer
targeted drug delivery
lipid-based nanocarriers
pulmonary delivery
dry powder inhalers
aerosols
Online Access:https://www.mdpi.com/1424-8247/14/8/725

Similar Items

Similar Items